Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

Last updated: November 20, 2020
Sponsor: GlaxoSmithKline
Overall Status: Completed

Phase

4

Condition

Congestive Heart Failure

Chest Pain

Heart Failure

Treatment

N/A

Clinical Study ID

NCT00344513
105517/358
  • All Genders

Study Summary

This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Hospitalized for episode of worsening heart failure as primary cause of admission orsignificant heart failure symptoms that develop during the hospitalization when theinitial reason for admission was not heart failure.
  • Systolic dysfunction (LVEF < 40%) or heart failure symptoms in the setting ofpreserved systolic function (diastolic dysfunction).

Exclusion

Exclusion criteria:

  • This study has no exclusion criteria.

Study Design

Total Participants: 50000
Study Start date:
December 16, 2002
Estimated Completion Date:
June 30, 2005